Review

Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)

Alexander Tenenbaum^1,2*, Enrique Z Fisman^1,2 and Michael Motro^1,2

• * Corresponding author: Alexander Tenenbaum altenen@sheba.health.gov.il

Author Affiliations

¹ Cardiac Rehabilitation Institute, Sheba Medical Center, 52621 Tel-Hashomer, Israel

² Sackler Faculty of Medicine, Tel-Aviv University, 69978 Tel-Aviv, Israel

For all author emails, please log on.

Cardiovascular Diabetology 2003, 2:4 doi:10.1186/1475-2840-2-4

Published: 23 March 2003

Abstract

The metabolic syndrome is a highly prevalent clinical entity. The recent Adult Treatment Panel (ATP III) guidelines have called specific attention to the importance of targeting the cardiovascular risk factors of the metabolic syndrome as a method of risk reduction therapy. The main factors characteristic of this syndrome are abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, insulin resistance (with or without glucose intolerance), prothrombotic and proinflammatory states. An insulin resistance following nuclear peroxisome proliferator activated receptors (PPAR) deactivation (mainly obesity-related) is the key phase of metabolic syndrome initiation. Afterwards, there are 2 principal pathways of metabolic syndrome development: 1) with preserved pancreatic beta cells function and insulin hypersecretion which can compensate for insulin resistance. This pathway leads mainly to the macrovascular complications of metabolic syndrome; 2) with massive damage of pancreatic beta cells leading to progressively decrease of insulin secretion and to hyperglycemia (e.g. overt type 2 diabetes). This pathway leads to both microvascular and macrovascular complications. We suggest that a PPAR-based appraisal of metabolic syndrome and type 2 diabetes may improve our understanding of these diseases and set a basis for a comprehensive approach in their treatment.